Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy—A Single Center Prospective Cohort Study
Ron Ram(Tel Aviv University), David Hagin(University of Washington), Ronen Ben‐Ami(Tel Aviv University), Ofrat Beyar‐Katz(Rambam Health Care Campus), Yael Bar‐On(Tel Aviv University), Tal Freund(Tel Aviv University), Odelia Amit(Tel Aviv University), Sigi Kay(Tel Aviv University), Ronit Gold(Tel Aviv University), Nili Eilaty(Tel Aviv University), Tami Halperin(Tel Aviv Sourasky Medical Center), Chen Glait‐Santar(Tel Aviv University)
Cited by 14
Related Papers
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses
|mBio|2020|445
Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome
|Frontiers in Immunology|2018|186
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
|Blood Advances|2021|170
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
|Transplantation and Cellular Therapy|2021|164